Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Mental Health Medication Recalls

Recalls of antidepressants, anti-anxiety and related psychiatric medications.

224 recalls in this category, newest first.

Class II · Moderate risk

Alprazolam Tablets

CGMP Deviations: Potential risk of Cross Contamination

Terminated Cross-contamination Breckenridge Pharmaceutical, Inc NDC 51991-0706-01 D-0460-2023
Class II · Moderate risk

Alprazolam Tablets

CGMP Deviations: Potential risk of Cross Contamination

Terminated Cross-contamination Breckenridge Pharmaceutical, Inc NDC 51991-0705-01 D-0459-2023
Class II · Moderate risk

Alprazolam Tablets

CGMP Deviations: Potential risk of Cross Contamination

Terminated Cross-contamination Breckenridge Pharmaceutical, Inc NDC 51991-0704-01 D-0458-2023
Class III · Low risk

buPROPion Hydrochloride Extended-Release Tablet

Presence Of Foreign Substance: Customer complaint for the presence of dark, gritty substance found within the bottle which was determined to be activated carbon from the desiccant canister inside the bottle.

Terminated Particulate / foreign matter Sun Pharmaceutical Industries INC NDC 47335-738-86 D-0858-2022
Class III · Low risk

buPROPion Hydrochloride Extended-Release Tablet

Presence Of Foreign Substance: Customer complaint for the presence of dark, gritty substance found within the bottle which was determined to be activated carbon from the desiccant canister inside the bottle.

Terminated Particulate / foreign matter Sun Pharmaceutical Industries INC D-0857-2022
Class II · Moderate risk

Xanax XR (alprazolam)

Failed Dissolution Specifications: low out of specification results for dissolution.

Terminated Dissolution failure Viatris Inc NDC 0009-0068-07 D-0854-2022
Class II · Moderate risk

Alprazolam C-IV 2 mg

CGMP Deviations: The Recall is due to the potential cross-contamination at the contract manufacturer (Ultra Tab Laboratories Inc.)

Terminated Cross-contamination Direct Rx NDC 72189-0058-60 D-0651-2022
Class II · Moderate risk

Alprazolam Tablets

CGMP Deviation: Potential cross-contamination with other drug substance during the manufacturing process.

Terminated Cross-contamination Golden State Medical Supply Inc. NDC 60429-504-18 D-0654-2022
Class II · Moderate risk

CITALOPRAM Tablets

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare D-0173-2024
Class II · Moderate risk

Venlafaxine Tablets

Presence of Forein Tablets/Capsules; Venlafaxine Tablets, USP 37.5 mg found in bottles labeled as Venlafaxine Tablets, USP, 50 mg

Terminated Labeling / mix-up Sun Pharmaceutical Industries INC NDC 16714-657-01 D-0703-2021
Class III · Low risk

Citalopram Oral Solution

Failed Impurities/Degradation Specifications; high out of specification results obtained at the 9 month stability timepoint

Terminated Impurity / degradation PAI Holdings, LLC. dba Pharmaceutical Associates Inc NDC 0121-1696-40 D-0015-2021
Class III · Low risk

Clonazepam Orally Disintegrating Tablets

Cross contamination with other products - OOS discovered during routine stability testing for highest unknown impurity later identified as clozapine

Terminated Cross-contamination Sun Pharmaceutical Industries INC NDC 57664-783-86 D-1445-2020
Class III · Low risk

Quetiapine Fumarate Extended-Release Tablets

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Terminated Labeling / mix-up The Harvard Drug Group D-1002-2020
Class III · Low risk

Quetiapine Fumarate Extended-Release Tablets

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Terminated Labeling / mix-up The Harvard Drug Group D-1001-2020
Class III · Low risk

Quetiapine Fumarate Extended-Release Tablets

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Terminated Labeling / mix-up The Harvard Drug Group D-1000-2020